Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Factor XIa Inhibitors’ Future Position in AF
Author(s): Maki Komiyama , Moritake Iguchi , Hiromichi Wada , et al Added: 1 year ago

Anticoagulation
Factor XI Inhibition and AF
Author(s): Bianca Rocca , Hugo ten Cate Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
SGLT2 Inhibitors in Acute Heart Failure
Author(s): Hugo Prado-Prado , Sergio Raposeiras-Roubín Added: 2 months ago

Heart Failure
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors
Author(s): Christina Magnussen Added: 1 year ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more

Cardiovascular Kidney Metabolic
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 11 months ago

Anticoagulation

Prevention & Chronic Conditions
Symptomology, Outcomes and Risk Factors of Acute Coronary Syndrome Presentations without Cardiac Chest Pain: A Scoping Review
Author(s): Meriem Perona , Amanda Cooklin , Christopher Thorpe , et al Added: 1 year ago

MI/ACS
SOUL: Oral Semaglutide Improves CV Risk Factors in T2D
Added: 3 weeks ago Source:  Radcliffe CKM
Mirjam Boros, Radcliffe CardiologyA post hoc secondary analysis of the SOUL trial has found that once-daily oral semaglutide is associated with early and sustained improvements in multiple cardiovascular (CV) risk factors in high-risk patients with type 2 diabetes (T2D).¹ These findings help to explain the mechanisms behind the primary trial results, which showed a 14% reduction in major adverse… View more

Cardiovascular Kidney Metabolic

Heart Failure
30th Annual Meeting of the ISCP
Author(s): Cristina Helguera Amezua , Laura Pérez Bacigalupe , Diego Manuel de la Eranueva , et al Added: 1 month ago

Prevention & Chronic Conditions

Anticoagulation
30th Annual Meeting of the ISCP
Author(s): Alberto Alen Andrés , María Salgado , Maria Fernández García , et al Added: 1 month ago

Prevention & Chronic Conditions

Heart Failure
AHA 25: The CORALreef HeFH Trial
Author(s): Christie Ballantyne Added: 6 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with… View more

Cardiovascular Kidney Metabolic